79 related articles for article (PubMed ID: 16564572)
21. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
Rodrigues MS; Sattler M
J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
[No Abstract] [Full Text] [Related]
22. Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance.
Travis J
Science; 2004 Jul; 305(5682):319-21. PubMed ID: 15256643
[No Abstract] [Full Text] [Related]
23. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
[No Abstract] [Full Text] [Related]
24. Transgenomic's WAVE System used for the early detection of drug resistance mutations in chronic myeloid leukemia.
Pharmacogenomics; 2005 Jul; 6(5):458-9. PubMed ID: 16013994
[No Abstract] [Full Text] [Related]
25. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
26. Counterpoint: Data first.
Golub T
Nature; 2010 Apr; 464(7289):679. PubMed ID: 20360719
[No Abstract] [Full Text] [Related]
27. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
[TBL] [Abstract][Full Text] [Related]
28. Cancer biology: summing up cancer stem cells.
Huntly BJ; Gilliland DG
Nature; 2005 Jun; 435(7046):1169-70. PubMed ID: 15988505
[No Abstract] [Full Text] [Related]
29. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
30. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
31. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
32. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
[No Abstract] [Full Text] [Related]
33. Clone wars in CML.
Giles FJ
Leukemia; 2006 Jun; 20(6):939-40. PubMed ID: 16721384
[No Abstract] [Full Text] [Related]
34. New leukemia drug shows promise against Gleevec resistance.
Ashraf H
Drug Discov Today; 2005 Apr; 10(7):453-4. PubMed ID: 15809187
[No Abstract] [Full Text] [Related]
35. Introduction: chronic myelogenous leukemia (CML).
Jabbour E; Kantarjian H
Semin Hematol; 2007 Jan; 44(1 Suppl 1):S1-3. PubMed ID: 17292735
[No Abstract] [Full Text] [Related]
36. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
Press RD; Galderisi C; Yang R; Rempfer C; Willis SG; Mauro MJ; Druker BJ; Deininger MW
Clin Cancer Res; 2007 Oct; 13(20):6136-43. PubMed ID: 17947479
[TBL] [Abstract][Full Text] [Related]
37. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242
[No Abstract] [Full Text] [Related]
38. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
39. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
[TBL] [Abstract][Full Text] [Related]
40. Unable to resist.
Brooksbank C
Nat Rev Cancer; 2002 Apr; 2(4):248. PubMed ID: 12001985
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]